Water

Water

SCHEMBL316719

O.Sn1cnc2cncnc21

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 1/20 0.41
HDAC1 known ✓ Q13547 1/20 0.36
HDAC6 known ✓ Q9UBN7 1/20 0.36
MEN1 known ✓ O00255 1/20 0.35
LTA4H P09960 1/20 0.35
CYP1A2 P05177 7/20 0.35
ALDH1A1 P00352 6/20 0.35
CYP2C19 P33261 5/20 0.35
CYP3A4 P08684 5/20 0.35
CYP2C9 P11712 5/20 0.35
TSHR P16473 4/20 0.35
LMNA P02545 3/20 0.35
HBB P68871 1/20 0.35
KMT2A Q03164 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
USP2 O75604 3/20 0.33
CLK4 Q9HAZ1 2/20 0.32
CYP2D6 P10635 1/20 0.32
HSD17B10 Q99714 1/20 0.31
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28529 0.98 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL28659170 0.96 FDPS (0.41) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL671498 0.96 FDPS (0.41) FDPSHDAC1HDAC6LTA4HCYP1A2
Tetrahydrofuran SCHEMBL28855131 0.84 FDPS (0.35) FDPSHDAC1HDAC6LTA4HCYP1A2
Malonic Acid SCHEMBL28513650 0.83 HDAC1 (0.44) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL28340215 0.74 FDPS (0.44) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL7787139 0.72 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL10664500 0.72 FDPS (0.46) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL30341176 0.72 GRM5 (0.46) FDPSHDAC1HDAC6LTA4HCYP1A2
SCHEMBL5633 0.72 FDPS (0.42) FDPSHDAC1HDAC6LTA4HCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3411039-B1 MERCAPTOPURINE HEMIHYDRATE UNIV MICHIGAN REGENTS (US) 2020-06-24 EP claimed
US-10590137-B2 Mercaptopurine hemihydrate THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-03-17 US claimed
US-20190048010-A1 Mercaptopurine Hemihydrate NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-02-14 US claimed
EP-3411039-A1 MERCAPTOPURINE HEMIHYDRATE The Regents of The University of Michigan (US) 2018-12-12 EP claimed
WO-2017136488-A1 MERCAPTOPURINE HEMIHYDRATE THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-10 WO claimed
US-7901453-B2 Coated implantable medical device COOK INCORPORATED (US) 2011-03-08 US claimed
US-20080145399-A1 coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer COOK MEDICAL TECHNOLOGIES LLC 2008-06-19 US claimed
US-20080145398-A1 coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2008-06-19 US claimed
US-20030036794-A1 Coated implantable medical device COOK INCORPORATED 2003-02-20 US claimed
US-10695349-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2020-06-30 US disclosed
EP-3411039-B1 MERCAPTOPURINE HEMIHYDRATE UNIV MICHIGAN REGENTS (US) 2020-06-24 EP disclosed
US-10590137-B2 Mercaptopurine hemihydrate THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-03-17 US disclosed
EP-3029041-B1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORP (US) 2020-03-04 EP disclosed
US-10575972-B2 Medical device with induction triggered anchors and system for deployment of the same COOK MEDICAL TECHNOLOGIES LLC (US) 2020-03-03 US disclosed
WO-2003035075-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-05-01 WO disclosed
US-20030036794-A1 Coated implantable medical device COOK INCORPORATED 2003-02-20 US disclosed
US-6518277-B1 Disrupting leukocyte function ICOS CORPORATION 2003-02-11 US disclosed
EP-1278748-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-01-29 EP disclosed
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION, A DELAWARE CORPORATION 2002-10-31 US disclosed
WO-2001081346-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives PIK3CD, PIK3CA, PIK3CG FDPS 2780/4885HDAC1 1833/4885HDAC6 2844/4885
US-10590137-B2 Mercaptopurine hemihydrate TPMT, MTHFD2, MSH2 FDPS 381/4885HDAC1 2885/4885HDAC6 2164/4885
US-10695349-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG FDPS 3023/4885HDAC1 897/4885HDAC6 1189/4885
US-20190048010-A1 Mercaptopurine Hemihydrate TPMT, MTHFD2, MSH2 FDPS 381/4885HDAC1 2885/4885HDAC6 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.